nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Conjunctival oedema—Carmustine—melanoma	0.0233	0.0396	CcSEcCtD
Apraclonidine—Hyperaemia—Carmustine—melanoma	0.0214	0.0364	CcSEcCtD
Apraclonidine—Visual acuity reduced—Temozolomide—melanoma	0.0105	0.0179	CcSEcCtD
Apraclonidine—Parosmia—Temozolomide—melanoma	0.00964	0.0164	CcSEcCtD
Apraclonidine—Lacrimation—Docetaxel—melanoma	0.00707	0.012	CcSEcCtD
Apraclonidine—Infestation NOS—Vemurafenib—melanoma	0.00685	0.0116	CcSEcCtD
Apraclonidine—Infestation—Vemurafenib—melanoma	0.00685	0.0116	CcSEcCtD
Apraclonidine—Coordination abnormal—Carmustine—melanoma	0.00659	0.0112	CcSEcCtD
Apraclonidine—Parosmia—Docetaxel—melanoma	0.00641	0.0109	CcSEcCtD
Apraclonidine—Coordination abnormal—Temozolomide—melanoma	0.00637	0.0108	CcSEcCtD
Apraclonidine—Oedema peripheral—Vemurafenib—melanoma	0.00605	0.0103	CcSEcCtD
Apraclonidine—Dry eye—Temozolomide—melanoma	0.00578	0.00981	CcSEcCtD
Apraclonidine—Eye disorder—Vemurafenib—melanoma	0.00574	0.00975	CcSEcCtD
Apraclonidine—Abnormal vision—Carmustine—melanoma	0.00564	0.00959	CcSEcCtD
Apraclonidine—Angiopathy—Vemurafenib—melanoma	0.00558	0.00947	CcSEcCtD
Apraclonidine—Mediastinal disorder—Vemurafenib—melanoma	0.00554	0.00941	CcSEcCtD
Apraclonidine—Abnormal vision—Temozolomide—melanoma	0.00546	0.00926	CcSEcCtD
Apraclonidine—Erythema—Vemurafenib—melanoma	0.00535	0.00909	CcSEcCtD
Apraclonidine—Dysgeusia—Vemurafenib—melanoma	0.00524	0.0089	CcSEcCtD
Apraclonidine—Eye pain—Carmustine—melanoma	0.0052	0.00884	CcSEcCtD
Apraclonidine—Rhinorrhoea—Docetaxel—melanoma	0.00513	0.00872	CcSEcCtD
Apraclonidine—Eye pain—Temozolomide—melanoma	0.00503	0.00854	CcSEcCtD
Apraclonidine—Eye irritation—Docetaxel—melanoma	0.00487	0.00827	CcSEcCtD
Apraclonidine—Myalgia—Vemurafenib—melanoma	0.00455	0.00774	CcSEcCtD
Apraclonidine—Face oedema—Carmustine—melanoma	0.00454	0.0077	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00452	0.00768	CcSEcCtD
Apraclonidine—Lacrimation increased—Docetaxel—melanoma	0.00451	0.00767	CcSEcCtD
Apraclonidine—Face oedema—Temozolomide—melanoma	0.00438	0.00744	CcSEcCtD
Apraclonidine—Infection—Vemurafenib—melanoma	0.00434	0.00737	CcSEcCtD
Apraclonidine—Inflammation—Docetaxel—melanoma	0.00429	0.00728	CcSEcCtD
Apraclonidine—Nervous system disorder—Vemurafenib—melanoma	0.00428	0.00727	CcSEcCtD
Apraclonidine—Skin disorder—Vemurafenib—melanoma	0.00424	0.0072	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00398	0.00676	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00377	0.0064	CcSEcCtD
Apraclonidine—Fatigue—Vemurafenib—melanoma	0.00376	0.00639	CcSEcCtD
Apraclonidine—Constipation—Vemurafenib—melanoma	0.00373	0.00634	CcSEcCtD
Apraclonidine—Haemorrhage—Bleomycin—melanoma	0.00372	0.00632	CcSEcCtD
Apraclonidine—Infestation NOS—Temozolomide—melanoma	0.0035	0.00594	CcSEcCtD
Apraclonidine—Infestation—Temozolomide—melanoma	0.0035	0.00594	CcSEcCtD
Apraclonidine—Pharyngitis—Dactinomycin—melanoma	0.00345	0.00585	CcSEcCtD
Apraclonidine—Haemorrhage—Carmustine—melanoma	0.00325	0.00552	CcSEcCtD
Apraclonidine—Erythema—Bleomycin—melanoma	0.00324	0.00551	CcSEcCtD
Apraclonidine—Hypersensitivity—Vemurafenib—melanoma	0.00322	0.00546	CcSEcCtD
Apraclonidine—Oedema peripheral—Carmustine—melanoma	0.0032	0.00544	CcSEcCtD
Apraclonidine—Haemorrhage—Temozolomide—melanoma	0.00314	0.00533	CcSEcCtD
Apraclonidine—Asthenia—Vemurafenib—melanoma	0.00313	0.00532	CcSEcCtD
Apraclonidine—Visual impairment—Carmustine—melanoma	0.00313	0.00532	CcSEcCtD
Apraclonidine—Pharyngitis—Temozolomide—melanoma	0.00312	0.00529	CcSEcCtD
Apraclonidine—Oedema peripheral—Temozolomide—melanoma	0.00309	0.00526	CcSEcCtD
Apraclonidine—Pruritus—Vemurafenib—melanoma	0.00309	0.00525	CcSEcCtD
Apraclonidine—Eye disorder—Carmustine—melanoma	0.00304	0.00516	CcSEcCtD
Apraclonidine—Visual impairment—Temozolomide—melanoma	0.00303	0.00514	CcSEcCtD
Apraclonidine—Erythema—Dactinomycin—melanoma	0.00302	0.00513	CcSEcCtD
Apraclonidine—Ill-defined disorder—Bleomycin—melanoma	0.00301	0.00511	CcSEcCtD
Apraclonidine—Diarrhoea—Vemurafenib—melanoma	0.00299	0.00507	CcSEcCtD
Apraclonidine—Eye disorder—Temozolomide—melanoma	0.00294	0.00499	CcSEcCtD
Apraclonidine—Malaise—Bleomycin—melanoma	0.00292	0.00496	CcSEcCtD
Apraclonidine—Arrhythmia—Carmustine—melanoma	0.0029	0.00493	CcSEcCtD
Apraclonidine—Dizziness—Vemurafenib—melanoma	0.00289	0.0049	CcSEcCtD
Apraclonidine—Angiopathy—Temozolomide—melanoma	0.00285	0.00484	CcSEcCtD
Apraclonidine—Mental disorder—Carmustine—melanoma	0.00285	0.00484	CcSEcCtD
Apraclonidine—Mediastinal disorder—Temozolomide—melanoma	0.00283	0.00481	CcSEcCtD
Apraclonidine—Erythema—Carmustine—melanoma	0.00283	0.00481	CcSEcCtD
Apraclonidine—Ill-defined disorder—Dactinomycin—melanoma	0.0028	0.00476	CcSEcCtD
Apraclonidine—Vomiting—Vemurafenib—melanoma	0.00278	0.00472	CcSEcCtD
Apraclonidine—Chest pain—Bleomycin—melanoma	0.00276	0.00469	CcSEcCtD
Apraclonidine—Myalgia—Bleomycin—melanoma	0.00276	0.00469	CcSEcCtD
Apraclonidine—Mental disorder—Temozolomide—melanoma	0.00275	0.00467	CcSEcCtD
Apraclonidine—Dermatitis—Vemurafenib—melanoma	0.00275	0.00467	CcSEcCtD
Apraclonidine—Headache—Vemurafenib—melanoma	0.00274	0.00465	CcSEcCtD
Apraclonidine—Erythema—Temozolomide—melanoma	0.00273	0.00464	CcSEcCtD
Apraclonidine—Discomfort—Bleomycin—melanoma	0.00273	0.00463	CcSEcCtD
Apraclonidine—Malaise—Dactinomycin—melanoma	0.00273	0.00463	CcSEcCtD
Apraclonidine—Nasopharyngitis—Docetaxel—melanoma	0.0027	0.00459	CcSEcCtD
Apraclonidine—Dysgeusia—Temozolomide—melanoma	0.00268	0.00455	CcSEcCtD
Apraclonidine—Vision blurred—Carmustine—melanoma	0.00267	0.00453	CcSEcCtD
Apraclonidine—Oedema—Bleomycin—melanoma	0.00265	0.00449	CcSEcCtD
Apraclonidine—Infection—Bleomycin—melanoma	0.00263	0.00446	CcSEcCtD
Apraclonidine—Nausea—Vemurafenib—melanoma	0.00259	0.0044	CcSEcCtD
Apraclonidine—Vision blurred—Temozolomide—melanoma	0.00258	0.00438	CcSEcCtD
Apraclonidine—Myalgia—Dactinomycin—melanoma	0.00257	0.00437	CcSEcCtD
Apraclonidine—Discomfort—Dactinomycin—melanoma	0.00254	0.00432	CcSEcCtD
Apraclonidine—Ill-defined disorder—Temozolomide—melanoma	0.00254	0.00431	CcSEcCtD
Apraclonidine—Oedema—Dactinomycin—melanoma	0.00247	0.00419	CcSEcCtD
Apraclonidine—Malaise—Temozolomide—melanoma	0.00247	0.00419	CcSEcCtD
Apraclonidine—Infection—Dactinomycin—melanoma	0.00245	0.00416	CcSEcCtD
Apraclonidine—Palpitations—Temozolomide—melanoma	0.00242	0.0041	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Bleomycin—melanoma	0.00241	0.00409	CcSEcCtD
Apraclonidine—Chest pain—Carmustine—melanoma	0.00241	0.00409	CcSEcCtD
Apraclonidine—Myalgia—Carmustine—melanoma	0.00241	0.00409	CcSEcCtD
Apraclonidine—Paraesthesia—Bleomycin—melanoma	0.00238	0.00403	CcSEcCtD
Apraclonidine—Dyspnoea—Bleomycin—melanoma	0.00236	0.00401	CcSEcCtD
Apraclonidine—Myalgia—Temozolomide—melanoma	0.00233	0.00395	CcSEcCtD
Apraclonidine—Infestation NOS—Docetaxel—melanoma	0.00233	0.00395	CcSEcCtD
Apraclonidine—Infestation—Docetaxel—melanoma	0.00233	0.00395	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00231	0.00393	CcSEcCtD
Apraclonidine—Oedema—Carmustine—melanoma	0.00231	0.00392	CcSEcCtD
Apraclonidine—Discomfort—Temozolomide—melanoma	0.0023	0.00391	CcSEcCtD
Apraclonidine—Infection—Carmustine—melanoma	0.00229	0.0039	CcSEcCtD
Apraclonidine—Dry mouth—Temozolomide—melanoma	0.00228	0.00387	CcSEcCtD
Apraclonidine—Pain—Bleomycin—melanoma	0.00226	0.00384	CcSEcCtD
Apraclonidine—Conjunctivitis—Docetaxel—melanoma	0.00226	0.00384	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00225	0.00382	CcSEcCtD
Apraclonidine—Oedema—Temozolomide—melanoma	0.00223	0.00379	CcSEcCtD
Apraclonidine—Infection—Temozolomide—melanoma	0.00222	0.00377	CcSEcCtD
Apraclonidine—Nervous system disorder—Temozolomide—melanoma	0.00219	0.00372	CcSEcCtD
Apraclonidine—Feeling abnormal—Bleomycin—melanoma	0.00218	0.0037	CcSEcCtD
Apraclonidine—Skin disorder—Temozolomide—melanoma	0.00217	0.00368	CcSEcCtD
Apraclonidine—Fatigue—Dactinomycin—melanoma	0.00213	0.00361	CcSEcCtD
Apraclonidine—Pain—Dactinomycin—melanoma	0.00211	0.00358	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Carmustine—melanoma	0.0021	0.00357	CcSEcCtD
Apraclonidine—Rhinitis—Docetaxel—melanoma	0.00209	0.00356	CcSEcCtD
Apraclonidine—Haemorrhage—Docetaxel—melanoma	0.00209	0.00355	CcSEcCtD
Apraclonidine—Insomnia—Carmustine—melanoma	0.00209	0.00355	CcSEcCtD
Apraclonidine—Paraesthesia—Carmustine—melanoma	0.00207	0.00352	CcSEcCtD
Apraclonidine—Pharyngitis—Docetaxel—melanoma	0.00207	0.00352	CcSEcCtD
Apraclonidine—Dyspnoea—Carmustine—melanoma	0.00206	0.0035	CcSEcCtD
Apraclonidine—Oedema peripheral—Docetaxel—melanoma	0.00206	0.00349	CcSEcCtD
Apraclonidine—Somnolence—Carmustine—melanoma	0.00205	0.00349	CcSEcCtD
Apraclonidine—Feeling abnormal—Dactinomycin—melanoma	0.00203	0.00345	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Temozolomide—melanoma	0.00203	0.00345	CcSEcCtD
Apraclonidine—Insomnia—Temozolomide—melanoma	0.00202	0.00343	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Dactinomycin—melanoma	0.00202	0.00343	CcSEcCtD
Apraclonidine—Visual impairment—Docetaxel—melanoma	0.00201	0.00342	CcSEcCtD
Apraclonidine—Paraesthesia—Temozolomide—melanoma	0.002	0.0034	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Carmustine—melanoma	0.00199	0.00339	CcSEcCtD
Apraclonidine—Dyspnoea—Temozolomide—melanoma	0.00199	0.00338	CcSEcCtD
Apraclonidine—Somnolence—Temozolomide—melanoma	0.00198	0.00337	CcSEcCtD
Apraclonidine—Pain—Carmustine—melanoma	0.00197	0.00335	CcSEcCtD
Apraclonidine—Constipation—Carmustine—melanoma	0.00197	0.00335	CcSEcCtD
Apraclonidine—Eye disorder—Docetaxel—melanoma	0.00195	0.00332	CcSEcCtD
Apraclonidine—Abdominal pain—Dactinomycin—melanoma	0.00195	0.00331	CcSEcCtD
Apraclonidine—Hypersensitivity—Bleomycin—melanoma	0.00195	0.00331	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Temozolomide—melanoma	0.00193	0.00327	CcSEcCtD
Apraclonidine—Fatigue—Temozolomide—melanoma	0.00192	0.00327	CcSEcCtD
Apraclonidine—Constipation—Temozolomide—melanoma	0.00191	0.00324	CcSEcCtD
Apraclonidine—Pain—Temozolomide—melanoma	0.00191	0.00324	CcSEcCtD
Apraclonidine—Feeling abnormal—Carmustine—melanoma	0.0019	0.00323	CcSEcCtD
Apraclonidine—Asthenia—Bleomycin—melanoma	0.0019	0.00322	CcSEcCtD
Apraclonidine—Angiopathy—Docetaxel—melanoma	0.0019	0.00322	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Carmustine—melanoma	0.00189	0.00321	CcSEcCtD
Apraclonidine—Mediastinal disorder—Docetaxel—melanoma	0.00188	0.0032	CcSEcCtD
Apraclonidine—Pruritus—Bleomycin—melanoma	0.00187	0.00318	CcSEcCtD
Apraclonidine—Arrhythmia—Docetaxel—melanoma	0.00187	0.00317	CcSEcCtD
Apraclonidine—Feeling abnormal—Temozolomide—melanoma	0.00184	0.00312	CcSEcCtD
Apraclonidine—Mental disorder—Docetaxel—melanoma	0.00183	0.00311	CcSEcCtD
Apraclonidine—Abdominal pain—Carmustine—melanoma	0.00183	0.0031	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Temozolomide—melanoma	0.00182	0.0031	CcSEcCtD
Apraclonidine—Erythema—Docetaxel—melanoma	0.00182	0.00309	CcSEcCtD
Apraclonidine—Hypersensitivity—Dactinomycin—melanoma	0.00182	0.00309	CcSEcCtD
Apraclonidine—Dysgeusia—Docetaxel—melanoma	0.00178	0.00302	CcSEcCtD
Apraclonidine—Asthenia—Dactinomycin—melanoma	0.00177	0.00301	CcSEcCtD
Apraclonidine—Abdominal pain—Temozolomide—melanoma	0.00176	0.003	CcSEcCtD
Apraclonidine—Hypersensitivity—Carmustine—melanoma	0.0017	0.00289	CcSEcCtD
Apraclonidine—Diarrhoea—Dactinomycin—melanoma	0.00169	0.00287	CcSEcCtD
Apraclonidine—Vomiting—Bleomycin—melanoma	0.00168	0.00286	CcSEcCtD
Apraclonidine—Dermatitis—Bleomycin—melanoma	0.00167	0.00283	CcSEcCtD
Apraclonidine—Asthenia—Carmustine—melanoma	0.00166	0.00281	CcSEcCtD
Apraclonidine—Hypersensitivity—Temozolomide—melanoma	0.00164	0.00279	CcSEcCtD
Apraclonidine—Syncope—Docetaxel—melanoma	0.00163	0.00277	CcSEcCtD
Apraclonidine—Palpitations—Docetaxel—melanoma	0.00161	0.00273	CcSEcCtD
Apraclonidine—Asthenia—Temozolomide—melanoma	0.0016	0.00272	CcSEcCtD
Apraclonidine—Diarrhoea—Carmustine—melanoma	0.00158	0.00268	CcSEcCtD
Apraclonidine—Pruritus—Temozolomide—melanoma	0.00158	0.00268	CcSEcCtD
Apraclonidine—Nausea—Bleomycin—melanoma	0.00157	0.00267	CcSEcCtD
Apraclonidine—Vomiting—Dactinomycin—melanoma	0.00157	0.00266	CcSEcCtD
Apraclonidine—Chest pain—Docetaxel—melanoma	0.00155	0.00263	CcSEcCtD
Apraclonidine—Myalgia—Docetaxel—melanoma	0.00155	0.00263	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00154	0.00261	CcSEcCtD
Apraclonidine—Dizziness—Carmustine—melanoma	0.00153	0.00259	CcSEcCtD
Apraclonidine—Diarrhoea—Temozolomide—melanoma	0.00153	0.00259	CcSEcCtD
Apraclonidine—Dry mouth—Docetaxel—melanoma	0.00151	0.00257	CcSEcCtD
Apraclonidine—Oedema—Docetaxel—melanoma	0.00148	0.00252	CcSEcCtD
Apraclonidine—Dizziness—Temozolomide—melanoma	0.00148	0.00251	CcSEcCtD
Apraclonidine—Infection—Docetaxel—melanoma	0.00147	0.0025	CcSEcCtD
Apraclonidine—Vomiting—Carmustine—melanoma	0.00147	0.00249	CcSEcCtD
Apraclonidine—Nausea—Dactinomycin—melanoma	0.00147	0.00249	CcSEcCtD
Apraclonidine—Nervous system disorder—Docetaxel—melanoma	0.00146	0.00247	CcSEcCtD
Apraclonidine—Dermatitis—Carmustine—melanoma	0.00145	0.00247	CcSEcCtD
Apraclonidine—Headache—Carmustine—melanoma	0.00145	0.00246	CcSEcCtD
Apraclonidine—Skin disorder—Docetaxel—melanoma	0.00144	0.00245	CcSEcCtD
Apraclonidine—Vomiting—Temozolomide—melanoma	0.00142	0.00241	CcSEcCtD
Apraclonidine—Dermatitis—Temozolomide—melanoma	0.00141	0.00239	CcSEcCtD
Apraclonidine—Headache—Temozolomide—melanoma	0.0014	0.00237	CcSEcCtD
Apraclonidine—Nausea—Carmustine—melanoma	0.00137	0.00233	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Docetaxel—melanoma	0.00135	0.0023	CcSEcCtD
Apraclonidine—Insomnia—Docetaxel—melanoma	0.00134	0.00228	CcSEcCtD
Apraclonidine—Paraesthesia—Docetaxel—melanoma	0.00133	0.00226	CcSEcCtD
Apraclonidine—Nausea—Temozolomide—melanoma	0.00133	0.00225	CcSEcCtD
Apraclonidine—Dyspnoea—Docetaxel—melanoma	0.00132	0.00225	CcSEcCtD
Apraclonidine—Somnolence—Docetaxel—melanoma	0.00132	0.00224	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Docetaxel—melanoma	0.00128	0.00218	CcSEcCtD
Apraclonidine—Fatigue—Docetaxel—melanoma	0.00128	0.00217	CcSEcCtD
Apraclonidine—Constipation—Docetaxel—melanoma	0.00127	0.00216	CcSEcCtD
Apraclonidine—Pain—Docetaxel—melanoma	0.00127	0.00216	CcSEcCtD
Apraclonidine—Feeling abnormal—Docetaxel—melanoma	0.00122	0.00208	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Docetaxel—melanoma	0.00121	0.00206	CcSEcCtD
Apraclonidine—Abdominal pain—Docetaxel—melanoma	0.00117	0.00199	CcSEcCtD
Apraclonidine—Hypersensitivity—Docetaxel—melanoma	0.00109	0.00186	CcSEcCtD
Apraclonidine—Asthenia—Docetaxel—melanoma	0.00106	0.00181	CcSEcCtD
Apraclonidine—Pruritus—Docetaxel—melanoma	0.00105	0.00178	CcSEcCtD
Apraclonidine—Diarrhoea—Docetaxel—melanoma	0.00102	0.00172	CcSEcCtD
Apraclonidine—Dizziness—Docetaxel—melanoma	0.000981	0.00167	CcSEcCtD
Apraclonidine—Vomiting—Docetaxel—melanoma	0.000944	0.0016	CcSEcCtD
Apraclonidine—Dermatitis—Docetaxel—melanoma	0.000935	0.00159	CcSEcCtD
Apraclonidine—Headache—Docetaxel—melanoma	0.00093	0.00158	CcSEcCtD
Apraclonidine—Nausea—Docetaxel—melanoma	0.000881	0.0015	CcSEcCtD
Apraclonidine—ADRA2C—Signaling Pathways—HIF1A—melanoma	7.41e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CB—melanoma	7.4e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PDGFRA—melanoma	7.36e-05	0.000179	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—melanoma	7.34e-05	0.000179	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PIK3CA—melanoma	7.3e-05	0.000178	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FN1—melanoma	7.3e-05	0.000178	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ITGB3—melanoma	7.28e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCA—melanoma	7.28e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CD86—melanoma	7.28e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—melanoma	7.28e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EDN1—melanoma	7.22e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOTCH1—melanoma	7.14e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SPP1—melanoma	7.14e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAP2K2—melanoma	7.12e-05	0.000173	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—melanoma	7.11e-05	0.000173	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KDR—melanoma	7.08e-05	0.000172	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—melanoma	7.06e-05	0.000172	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGF1—melanoma	7.06e-05	0.000172	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CSF2—melanoma	7.06e-05	0.000172	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CD80—melanoma	7e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APC—melanoma	6.99e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CG—melanoma	6.99e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KIT—melanoma	6.99e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—NRAS—melanoma	6.99e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL2—melanoma	6.95e-05	0.000169	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—E2F1—melanoma	6.91e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGF—melanoma	6.91e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CB—melanoma	6.88e-05	0.000167	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CD—melanoma	6.86e-05	0.000167	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDGFRA—melanoma	6.84e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FN1—melanoma	6.82e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL2—melanoma	6.8e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—melanoma	6.77e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TERT—melanoma	6.77e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ITGB3—melanoma	6.77e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCA—melanoma	6.77e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—HRAS—melanoma	6.76e-05	0.000164	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RAC1—melanoma	6.75e-05	0.000164	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK3—melanoma	6.69e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH1—melanoma	6.67e-05	0.000162	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SPP1—melanoma	6.64e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAP2K2—melanoma	6.62e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—melanoma	6.61e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—BRAF—melanoma	6.57e-05	0.00016	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CD80—melanoma	6.54e-05	0.000159	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CG—melanoma	6.53e-05	0.000159	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KIT—melanoma	6.53e-05	0.000159	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APC—melanoma	6.53e-05	0.000159	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—NRAS—melanoma	6.53e-05	0.000159	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIF1A—melanoma	6.48e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGF—melanoma	6.45e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—melanoma	6.4e-05	0.000156	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK1—melanoma	6.37e-05	0.000155	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—melanoma	6.36e-05	0.000155	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CG—melanoma	6.34e-05	0.000154	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL2—melanoma	6.31e-05	0.000154	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TERT—melanoma	6.29e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RAC1—melanoma	6.27e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK3—melanoma	6.25e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KDR—melanoma	6.19e-05	0.000151	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAP2K1—melanoma	6.18e-05	0.00015	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CD—melanoma	6.14e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BRAF—melanoma	6.13e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—melanoma	6.12e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—melanoma	6.08e-05	0.000148	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIF1A—melanoma	6.02e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—KRAS—melanoma	6.01e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CB—melanoma	5.98e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—melanoma	5.97e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—melanoma	5.97e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FN1—melanoma	5.96e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK1—melanoma	5.95e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—melanoma	5.95e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—melanoma	5.93e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGF2—melanoma	5.88e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH1—melanoma	5.83e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAP2K1—melanoma	5.77e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KDR—melanoma	5.75e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CD—melanoma	5.74e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CD80—melanoma	5.71e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CG—melanoma	5.7e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APC—melanoma	5.7e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KIT—melanoma	5.7e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—NRAS—melanoma	5.7e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—melanoma	5.68e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGF—melanoma	5.64e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—KRAS—melanoma	5.62e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CD—melanoma	5.57e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FN1—melanoma	5.54e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—melanoma	5.52e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MDM2—melanoma	5.5e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—melanoma	5.5e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGF2—melanoma	5.49e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK3—melanoma	5.46e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ERBB2—melanoma	5.42e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH1—melanoma	5.42e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BRAF—melanoma	5.36e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CB—melanoma	5.35e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CD80—melanoma	5.31e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APC—melanoma	5.3e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CG—melanoma	5.3e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KIT—melanoma	5.3e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—NRAS—melanoma	5.3e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGF—melanoma	5.24e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—melanoma	5.22e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK1—melanoma	5.2e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—melanoma	5.2e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTEN—melanoma	5.17e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—melanoma	5.16e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—melanoma	5.14e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MDM2—melanoma	5.14e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HRAS—melanoma	5.11e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK3—melanoma	5.08e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ERBB2—melanoma	5.07e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAP2K1—melanoma	5.05e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1B—melanoma	5.02e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CD—melanoma	5.01e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CB—melanoma	5e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BRAF—melanoma	4.98e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—melanoma	4.97e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	4.97e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—melanoma	4.92e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL2—melanoma	4.92e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—KRAS—melanoma	4.91e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—melanoma	4.89e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CB—melanoma	4.86e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—melanoma	4.85e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK1—melanoma	4.83e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—melanoma	4.83e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—melanoma	4.81e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—melanoma	4.81e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGF2—melanoma	4.8e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCND1—melanoma	4.79e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HRAS—melanoma	4.77e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CTNNB1—melanoma	4.75e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1B—melanoma	4.69e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAP2K1—melanoma	4.69e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CD—melanoma	4.66e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—melanoma	4.65e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—melanoma	4.64e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1A—melanoma	4.64e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTEN—melanoma	4.63e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	4.62e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NFKB1—melanoma	4.6e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—melanoma	4.6e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL2—melanoma	4.59e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—melanoma	4.57e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—KRAS—melanoma	4.56e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—melanoma	4.51e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	4.51e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MDM2—melanoma	4.49e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCND1—melanoma	4.48e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGF2—melanoma	4.46e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CTNNB1—melanoma	4.43e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ERBB2—melanoma	4.43e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CB—melanoma	4.37e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—melanoma	4.35e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1A—melanoma	4.33e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTEN—melanoma	4.32e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NFKB1—melanoma	4.3e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—melanoma	4.22e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—melanoma	4.2e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTEN—melanoma	4.2e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	4.19e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—melanoma	4.18e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MDM2—melanoma	4.17e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HRAS—melanoma	4.17e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—melanoma	4.14e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NRAS—melanoma	4.13e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB2—melanoma	4.12e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1B—melanoma	4.1e-05	9.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CB—melanoma	4.06e-05	9.88e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—melanoma	4.06e-05	9.87e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—melanoma	4.02e-05	9.78e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2—melanoma	4.01e-05	9.76e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—melanoma	3.99e-05	9.71e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK3—melanoma	3.95e-05	9.61e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCND1—melanoma	3.91e-05	9.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—melanoma	3.9e-05	9.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—melanoma	3.9e-05	9.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HRAS—melanoma	3.88e-05	9.43e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CTNNB1—melanoma	3.88e-05	9.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—melanoma	3.86e-05	9.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NRAS—melanoma	3.85e-05	9.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—melanoma	3.84e-05	9.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	3.81e-05	9.27e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—melanoma	3.8e-05	9.24e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1A—melanoma	3.79e-05	9.21e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTEN—melanoma	3.78e-05	9.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	3.77e-05	9.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK1—melanoma	3.76e-05	9.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—melanoma	3.76e-05	9.14e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NFKB1—melanoma	3.76e-05	9.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—melanoma	3.74e-05	9.08e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2—melanoma	3.73e-05	9.07e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—melanoma	3.71e-05	9.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK3—melanoma	3.69e-05	8.98e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—melanoma	3.68e-05	8.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—melanoma	3.65e-05	8.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCND1—melanoma	3.64e-05	8.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	3.6e-05	8.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—melanoma	3.59e-05	8.73e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KRAS—melanoma	3.55e-05	8.64e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—melanoma	3.53e-05	8.59e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	3.52e-05	8.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK1—melanoma	3.51e-05	8.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—melanoma	3.51e-05	8.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTEN—melanoma	3.51e-05	8.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NFKB1—melanoma	3.49e-05	8.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—melanoma	3.42e-05	8.33e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—melanoma	3.41e-05	8.3e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—melanoma	3.38e-05	8.22e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NRAS—melanoma	3.37e-05	8.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KRAS—melanoma	3.32e-05	8.07e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—melanoma	3.26e-05	7.94e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK3—melanoma	3.23e-05	7.85e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—melanoma	3.17e-05	7.71e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—melanoma	3.16e-05	7.68e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—melanoma	3.14e-05	7.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—melanoma	3.14e-05	7.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NRAS—melanoma	3.13e-05	7.61e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK1—melanoma	3.07e-05	7.47e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—melanoma	3.07e-05	7.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—melanoma	3.05e-05	7.41e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HRAS—melanoma	3.02e-05	7.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK3—melanoma	3e-05	7.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—melanoma	2.98e-05	7.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—melanoma	2.96e-05	7.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—melanoma	2.95e-05	7.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—melanoma	2.92e-05	7.09e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KRAS—melanoma	2.9e-05	7.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—melanoma	2.89e-05	7.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK1—melanoma	2.85e-05	6.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—melanoma	2.85e-05	6.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HRAS—melanoma	2.82e-05	6.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—melanoma	2.7e-05	6.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KRAS—melanoma	2.69e-05	6.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—melanoma	2.67e-05	6.48e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.66e-05	6.48e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—melanoma	2.58e-05	6.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—melanoma	2.49e-05	6.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	2.48e-05	6.02e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HRAS—melanoma	2.47e-05	6e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—melanoma	2.42e-05	5.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—melanoma	2.4e-05	5.82e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—melanoma	2.36e-05	5.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HRAS—melanoma	2.29e-05	5.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—melanoma	2.19e-05	5.33e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—melanoma	2.18e-05	5.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—melanoma	2.02e-05	4.92e-05	CbGpPWpGaD
